Inventiva S.A. (IVA) stock is soaring 5.08% in intraday trading, following a positive analyst report from Canaccord Genuity. The significant uptick comes as investors react to the reaffirmed confidence in the company's prospects.

In a report released earlier today, Canaccord Genuity analyst Edward Nash maintained a Buy rating on Inventiva, setting a price target of $20.00. This reaffirmation suggests that the analyst sees substantial upside potential for the stock, given its current trading price.

Analyst ratings and price targets often have a notable impact on stock prices, particularly for smaller biotech companies like Inventiva. The maintained Buy rating and the ambitious price target appear to have boosted investor confidence, contributing to today's significant stock price increase. As always, investors are advised to conduct their own research and consider multiple factors when making investment decisions.